Plasma Protein Therapeutics Market

The Global Plasma Protein Therapeutics Market is valued at USD 27.62 Billion in 2022 and is expected to reach USD 44.79 Billion by 2029 with a CAGR of 7.15% over the forecast period.

Global Plasma Protein Therapeutics Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2023-2029-  Increasing prevalence of autoimmune diseases, and rising number of research & development activities in this field are some of the major factors anticipated to drive the growth of the Global Plasma Protein Therapeutics Market within the forecast period.

Scope–

Plasma proteins also known as serum proteins or blood proteins are made up of simple and conjugated proteins present in blood plasma. The plasma proteins are required for blood clotting such as immunoglobulins and prothrombin. Plasma proteins help to maintain the osmotic pressure of the blood and hence the blood volume. Plasma proteins serve many functions such as transport of lipids, hormones, vitamins and minerals in activity and functioning of the immune system.

The Covid-19 pandemic has had a significant impact on the global plasma protein therapeutics market. Plasma protein therapies are crucial treatments for patients with rare and chronic diseases, but the pandemic has disrupted the collection of plasma and production of these therapies. A decrease in plasma donations due to lockdowns and social distancing measures has led to a shortage of plasma and affected the production of plasma-derived therapies. Additionally, many patients have delayed or skipped treatments, leading to decreased demand. However, the pandemic has also driven innovation in the plasma protein therapeutics market, with companies investing in research and development of new therapies, particularly for Covid-19 treatment.

The plasma protein therapeutics market is segmented on the basis of product, application and region & country level. On the basis of product, the plasma protein therapeutics market is segmented into immunoglobulin, albumin, plasma derived factor Vlll  and others. On the basis of application, the plasma protein therapeutics market is segmented into hemophilia, idiopathic thrombocytopenic purpura, primary immunodeficiencies  and other applications.

The regions covered in global plasma protein therapeutics market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global plasma protein therapeutics market is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

Key Players-

Some of the key players for plasma protein therapeutics market are -

• Takeda Pharmaceutical Company Limited
• Octapharma USA Inc.
• Baxter International
• Shire Plc.
• China Biologics.
• Biotests
• CSL Behring
• GRIFOLS
• S.A
• Kedrion
• others

Segmentation-

By Product:-

• Immunoglobulin
• Albumin
• Plasma Derived Factor Vlll
• Others

By Application:-

• Hemophilia
• Idiopathic Thrombocytopenic Purpura
• Primary Immunodeficiencies
• Other Applications

By Regional & Country Level:

• North America

  • U.S.
  • Canada

• Europe

  • U.K.
  • France
  • Germany
  • Italy

• Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

• Latin America

  • Brazil
  • Mexico

• Middle East and Africa

  • GCC
  • Africa
  • Rest of Middle East and Africa

Increasing Prevalence of Autoimmune Diseases, and Rising Number of Research & Development Activities in This Field are Some of the Major Factors Anticipated to Drive the Market Growth

One of the major factors driving the growth of the global plasma protein is increasing prevalence of autoimmune diseases. For instance; approximately 10 million people in U.S affected by autoimmune diseases. Albumin is a type of plasma protein made by the liver and circulated throughout the body via the bloodstream and an effective treatment for the autoimmune diseases. Hence, increasing number of autoimmune diseases is driving the demand for plasma protein. In addition, rising number of research and developments activities in this field are boosting the market growth of plasma protein therapeutics market. For instance; on March 10^th, 2022, Terumo blood and cell technologies' new plasma collection technology approved by U.S Food and Drug Administration.

Moreover, growing adoption of plasma protein in  neurological disease is also fueling market growth. Plasma exchange is a highly effective acute treatment for neuromyelitis optica spectrum disorders. Plasma exchange is used for neurological disorders and ongoing advancements in isolation techniques will continue fueling the growth in the plasma protein therapeutics within the forecast period.

However, the strict regulations for the handling of plasma protein products may hinder the growth of the plasma protein therapeutics market. In spite of that, growing investments in this field may provide more opportunities for the further growth of the market.

North America is Expected to Dominate the Global Plasma Protein Therapeutics Market

North America is expected to dominate the global plasma protein therapeutics market due rising burden of arthritis, highly developing healthcare infrastructure and increasing research and development activities in this field in this region. One of the major factors driving the global plasma protein therapeutics market in North America is increasing number of arthritis. For instance; as per the United States Arthritis Foundation 2019 report, arthritis is the main cause of disability among adults and it is anticipated to increase 49 percent to 78.4 million by 2040. In particular, patients with rheumatoid arthritis may benefit from plasma protein therapy as it can help to slow down the progression of the disease and reduce the severity of symptoms. Plasma protein therapy can also be helpful for patients with other forms of arthritis, such as juvenile idiopathic arthritis and psoriatic arthritis.

Europe is fastest growing region in the global plasma protein market due to rising number of neurological disorders, and technological advancements in this field in this region. In addition, prevalence of rare and chronic diseases such as hemophilia, immune deficiencies, and alpha-1 antitrypsin deficiency is increasing in Europe. For example; the European Hemophilia Consortium estimates that there are approximately 50,000 people with hemophilia in Europe. This has resulted in a growing demand for plasma protein therapeutics as a treatment option for these diseases.

News-

U.S. FDA Cleared Terumo Blood and Cell Technologies' New Plasma Collection Technology

On March 10^th, 2022; A the new plasma collection system developed by Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company approved by U.S Food and Drug Administration. Rika is a next-generation automated technology engrossed on the experience of plasma center employees and donors. It comprises safety features to lessen operator errors and collects plasma in 35 minutes or less. Rika will be introduced at CSL Plasma collection centers in the Denver, Colorado area.

Report Analysis	Details
Historical data	2016 - 2021
Forecast Period	2022 - 2029
Market Size in 2022:	USD 27.62 Billion
Base year considered	2021
Forecast Period CAGR %:	7.15%
Market Size Expected in 2029:	USD 44.79 Billion
Tables, Charts & Figures:	175
Pages	300
Key Players/Companies	Takeda Pharmaceutical Company Limited,  Octapharma USA, Inc.,  Baxter International,  Shire Plc., China Biologics., Biotests, CSL Behring, GRIFOLS, S.A, Kedrion and others
Segments Covered	By Product, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa